^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hodgkin Lymphoma

    Related cancers:
    3d
    Identifying genes and pathways in familial lymphoid cancers using whole exome sequencing. (PubMed, Leuk Lymphoma)
    Some variants appeared to segregate with specific types of lymphoid cancers; others were shared across different subtypes. Identifying factors predisposing to different types of lymphoid cancers will help understand the etiology of these neoplasms.
    Journal
    |
    TLE3 (TLE Family Member 3, Transcriptional Corepressor) • BCL9 (BCL9 Transcription Coactivator)
    4d
    NCI-2018-02699: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, David Bond, MD | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs)
    4d
    Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) (clinicaltrials.gov)
    P1/2, N=137, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • favezelimab (MK-4280)
    4d
    An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, FBD Biologics Limited | Trial completion date: Aug 2026 --> May 2027 | Trial primary completion date: Aug 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    5d
    Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, St. Jude Children's Research Hospital | Initiation date: Jan 2026 --> Apr 2026
    Trial initiation date
    5d
    LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Nov 2033 | Trial primary completion date: Dec 2025 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    7d
    Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine. (PubMed, Discov Oncol)
    This review systematically summarizes the core mechanisms by which EBV contributes to lymphoma pathogenesis and evaluates the breakthroughs and challenges of current therapeutic strategies. It also outlines the future directions of precision medicine, based on multi-disciplinary integration, to enhance the understanding of the molecular pathology of EBV-associated lymphomas and optimize personalized treatment.
    Review • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    7d
    Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=84, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine • Adcetris (brentuximab vedotin) • dexamethasone
    8d
    Successful treatment with brentuximab vedotin for MYC positive syncytial variant nodular sclerosis Hodgkin lymphoma (PubMed, Rinsho Ketsueki)
    Furthermore, treatment with AVD (adriamycin/vinblastine/dacarbazine) in combination with brentuximab vedotin (BV) was initiated to achieve a complete metabolic response. Histopathologically, SV has a high proportion of HRS cells, with high CD30-positive and low EBER-positive rates. Therefore, CD30-targeted therapies such as BV may be preferable for SV, even in localized NS-HL patients, thereby improving patient prognosis.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
    9d
    LIFE-L: Lifestyle Intervention of Food and Exercise for Lymphoma Survivors (clinicaltrials.gov)
    P=N/A, N=140, Recruiting, University of Miami | Trial completion date: Jan 2026 --> Oct 2026 | Trial primary completion date: Jan 2026 --> Oct 2026
    Trial completion date • Trial primary completion date
    10d
    ZG005 combination hydrochloride gilteritinib tablets in patients with relapsed or refractory lymphoma: a multicentre, open-label, dose-exploration and dose-expansion phase I/II clinical study. (ChiCTR2500114728)
    P1/2, N=60, Recruiting, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine
    New P1/2 trial
    |
    Xospata (gilteritinib) • giredestrant (RG6171) • nilvanstomig (ZG005) • ravoxertinib (RG7842)
    10d
    Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=15, Completed, National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • SF3B1 (Splicing Factor 3b Subunit 1)
    |
    TP53 mutation • SF3B1 mutation
    |
    Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • fludarabine IV